

	Quarter ended			Year ended	
	31-03-2018	31-12-2017	31-03-2017	31-03-2018	31-03-2017
Particulars	Audited (Refer note 9)	Unaudited	Audited (Refer note 9)	Audited	Audited
Segment wise revenue and results					
Segment revenue: (Refer note 2)					
a) Pharmaceuticals	3,665.07	3,885.75	3,554.06	15,110.03	14,537.06
b) New ventures	34.26	36.89	28.32	134.78	95.29
Total segment revenue	3,699.33	3,922.64	3,582.38	15,244.81	14,632.35
Less : Intersegment revenue	1.36	8.82	0.38	25.56	2.11
Total Income from operations	3,697.97	3,913.82	3,582.00	15,219.25	14,630.24
Segment result:					
Profit/(loss) before tax and interest from each segment					
a) Pharmaceuticals	357.55	365.67	(7.54)	1,966.48	1,502.47
b) New ventures	(45.49)	(16.43)	(95.62)	(105.27)	(120.92)
Total segment result	312.06	349.24	(103.16)	1,861.21	1,381.55
Less: Finance costs	35.20	9.15	33.40	114.23	159.38
Profit (+)/loss (-) before exceptional item and tax	276.86	340.09	(136.56)	1,746.98	1,222.17
Less: Exceptional Item (Refer note 3)	77.52	-	•	77.52	-
Total Profit (+)/loss (-) before tax	199.34	340.09	(136,56)	1,669.46	1,222.17